

Company registration number 394287 (Republic of Ireland)

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

J.G. Carlin & Co. Limited

Chartered Certified Accountants, Statutory Auditors & Tax Advisors

The Business Centre

Lisfannon, Buncrana
Co. Donegal, F93 Y2NA.

Tel: +353 (0)74 9364200

Fax: +353 (0)74 9361955

Email: info@jgc.ie

**D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
CONTENTS**

	Page
Directors' responsibilities statement	1
Balance sheet	2 - 3
Statement of changes in equity	4
Notes to the financial statements	5 - 11

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 28 FEBRUARY 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (Generally accepted Accounting Practice in Ireland) issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for that financial year and otherwise comply with the Companies Act 2014.


In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

On behalf of the board


Mr Donal Cassidy
Director


Mr Liam Grimley
Director

7 November 2025

**D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
BALANCE SHEET**

AS AT 28 FEBRUARY 2025

	Notes	2025		2024	
		€	€	€	€
Fixed assets					
Tangible assets	6		73,005		80,652
Current assets					
Stocks	7	322,964		335,190	
Debtors	8	331,016		167,614	
Cash at bank and in hand		125,333		188,753	
		779,313		691,557	
Creditors: amounts falling due within one year	9	(358,229)		(341,472)	
Net current assets			421,084		350,085
Total assets less current liabilities			494,089		430,737
Provisions for liabilities			(37,006)		(30,860)
Net assets			457,083		399,877
Capital and reserves					
Called up share capital presented as equity			100		100
Profit and loss reserves			456,983		399,777
Total equity			457,083		399,877

**D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
BALANCE SHEET (CONTINUED)
AS AT 28 FEBRUARY 2025**

We, as directors of D J's Pharmacy Limited, state that:

(a) The company is availing itself of the exemption from audit provided for by Chapter 15 of Part 6 of the Companies Act 2014.

(b) The company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied.

(c) The shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2).

(d) The directors acknowledge the obligations of the company, under the Companies Act 2014:

(i) to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year; and

(ii) to otherwise comply with the provisions of this Act relating to financial statements so far as they are applicable to the company.

(e) The company has relied on the specified exemption contained in section 352 Companies Act 2014; the company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with Financial Reporting Standard 102 'The Financial Statement Reporting Standard applicable in the UK and Republic of Ireland'.

The financial statements were approved by the board of directors and authorised for issue on 7 November 2025 and are signed on its behalf by:


Mr Doral Cassidy
Director


Mr Liam Grimley
Director

**D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
STATEMENT OF CHANGES IN EQUITY**

FOR THE YEAR ENDED 28 FEBRUARY 2025

	Share capital	Profit and loss reserves	Total
	€	€	€
Balance at 1 March 2023	100	401,556	401,656
Year ended 29 February 2024:			
Loss and total comprehensive income	-	(1,779)	(1,779)
	<u>100</u>	<u>399,777</u>	<u>399,877</u>
Balance at 29 February 2024	100	399,777	399,877
Year ended 28 February 2025:			
Profit and total comprehensive income	-	57,206	57,206
	<u>100</u>	<u>456,983</u>	<u>457,083</u>
Balance at 28 February 2025	<u>100</u>	<u>456,983</u>	<u>457,083</u>

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025

1 Accounting policies

Company information

D J's Pharmacy Limited is a limited company domiciled and incorporated in the Republic of Ireland. The registered office is 43 Lower Main Street, Bunclrana, Co. Donegal and its company registration number is 394287.

1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), as adapted by Section 1A of FRS 102, and the requirements of the Companies Act 2014.

The financial statements are prepared in euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest €.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.3 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements	4% Straight line
Fixtures, fittings and equipment	15% Reducing balance
Computer equipment	15% Reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025

1 Accounting policies

(Continued)

1.4 Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.5 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6 Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025

1 Accounting policies

(Continued)

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9 Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

1.10 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025

1 Accounting policies

(Continued)

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.11 Provisions

Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

1.12 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14 Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.15 Foreign exchange

Transactions in currencies other than euros are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025

2 Judgements and key sources of estimation uncertainty

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Operating profit/(loss)

	2025	2024
	€	€
Operating profit/(loss) for the year is stated after charging:		
Depreciation of tangible fixed assets	9,947	11,045
	<u>9,947</u>	<u>11,045</u>

4 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

	2025	2024
	Number	Number
Total	18	16
	<u>18</u>	<u>16</u>

5 Directors' remuneration

	2025	2024
	€	€
Remuneration for qualifying services	450,067	465,564
Company pension contributions to defined contribution schemes	10,200	10,200
	<u>460,267</u>	<u>475,764</u>

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025

6 Tangible fixed assets

	Leasehold improvements	Fixtures, fittings and equipment	Computer equipment	Total
	€	€	€	€
Cost				
At 1 March 2024	36,635	300,529	17,823	354,987
Additions	-	-	2,300	2,300
	<u>36,635</u>	<u>300,529</u>	<u>20,123</u>	<u>357,287</u>
At 28 February 2025	36,635	300,529	20,123	357,287
Depreciation and impairment				
At 1 March 2024	10,255	255,485	8,595	274,335
Depreciation charged in the year	1,465	6,755	1,727	9,947
	<u>11,720</u>	<u>262,240</u>	<u>10,322</u>	<u>284,282</u>
At 28 February 2025	11,720	262,240	10,322	284,282
Carrying amount				
At 28 February 2025	<u>24,915</u>	<u>38,289</u>	<u>9,801</u>	<u>73,005</u>
At 29 February 2024	<u>26,380</u>	<u>45,044</u>	<u>9,228</u>	<u>80,652</u>

7 Stocks

	2025	2024
	€	€
Finished goods and goods for resale	322,964	335,190
	<u>322,964</u>	<u>335,190</u>

8 Debtors

	2025	2024
	€	€
Amounts falling due within one year:		
Trade debtors	243,558	94,454
Corporation tax recoverable	73,452	59,409
Prepayments	14,006	13,751
	<u>331,016</u>	<u>167,614</u>

D J'S PHARMACY LIMITED
T/A HEALTHWISE SLIGO PHARMACY
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025

9 Creditors: amounts falling due within one year

	Notes	2025 €	2024 €
Amounts owed to credit institutions		305	2,599
Trade creditors		309,028	304,348
Other creditors including tax and social insurance		28,771	21,124
Accruals		20,125	13,401
		<u>358,229</u>	<u>341,472</u>

Bank of Ireland holds a floating debenture over the assets and undertakings of the company. It also holds a letter of guarantee from Liam Grimley, James Cassidy and Donal Cassidy guaranteeing the borrower's liabilities supported by a First Legal Mortgage/Charge over the property at Lisfannon, Buncrana, Co. Donegal which is in their names.

10 Related party transactions

The following amounts were outstanding at the reporting end date:

	2025 €	2024 €
Amounts due to related parties		
Healthwise Pharmacies Limited	-	40,733
	<u>-</u>	<u>40,733</u>

The following amounts were outstanding at the reporting end date:

	2025 €	2024 €
Amounts due from related parties		
Healthwise Pharmacies Limited	106,790	-
	<u>106,790</u>	<u>-</u>

Healthwise Pharmacies Limited is related by virtue of common directors. The company made net purchases during the year from Healthwise Pharmacies Limited of €879,850 (2024: €914,643).

11 Approval of financial statements

The directors approved the financial statements on 7 November 2025.